U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H23N
Molecular Weight 277.4041
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMITRIPTYLINE

SMILES

CN(C)CCC=C1c2ccccc2CCc3ccccc31

InChI

InChIKey=KRMDCWKBEZIMAB-UHFFFAOYSA-N
InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H23N
Molecular Weight 277.4041
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://www.rxlist.com/elavil-drug.htm https://www.ncbi.nlm.nih.gov/pubmed/23235671; https://www.ncbi.nlm.nih.gov/pubmed/11157426; http://www.ncbi.nlm.nih.gov/pubmed/16871467; http://www.ncbi.nlm.nih.gov/pubmed/2578912; http://www.ncbi.nlm.nih.gov/pubmed/?term=15943846

Amitriptyline is a derivative of dibenzocycloheptadiene and a tricyclic antidepressant (TCA) and is mainly used to treat symptoms of depression. It works on the central nervous system (CNS) by inhibiting the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Amitriptyline has been frequently used as an active comparator in clinical trials on newer antidepressants. It is rarely used as a first-line antidepressant nowadays due to its high degree of toxicity in overdose and generally poorer tolerability than the newer antidepressants.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
3.45 nM [IC50]
Target ID: P31645
Gene ID: 6532.0
Gene Symbol: SLC6A4
Target Organism: Homo sapiens (Human)
13.3 nM [IC50]
Target ID: P28223
Gene ID: 3356.0
Gene Symbol: HTR2A
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
AMITRIPTYLINE HYDROCHLORIDE

Approved Use

For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states.

Launch Date

8.7393599E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.3 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
593 ng × h/mL
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.4 h
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.7%
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
Disc. AE: Bradycardia...
Other AEs: Agitation, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Bradycardia (grade 3, 20%)
Other AEs:
Agitation (20%)
Dry mouth (20%)
Drowsiness (20%)
Language disorder (20%)
Sources:
10 % 1 times / day single, topical
Highest studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
Other AEs: Thought disorder, Mental concentration difficult...
Other AEs:
Thought disorder
Mental concentration difficult
Sources:
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
healthy, mean age 22.1 years
n = 96
Health Status: healthy
Age Group: mean age 22.1 years
Sex: M+F
Population Size: 96
Sources:
Other AEs: Mental status changes...
Other AEs:
Mental status changes
Sources:
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Other AEs: Dry mouth, Sleepiness...
Other AEs:
Dry mouth (75%)
Sleepiness (68.8%)
Dizziness (25%)
Constipation (18.8%)
Palpitations (6.3%)
Malaise (6.3%)
Sources:
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Disc. AE: Drowsiness, Dry mouth...
Other AEs: Drowsiness, Nausea...
AEs leading to
discontinuation/dose reduction:
Drowsiness (10%)
Dry mouth (10%)
Other AEs:
Drowsiness (51.8%)
Nausea (7.4%)
Headache (7.4%)
Dry mouth (63%)
Thirst (7.4%)
Tiredness (7.4%)
Bad taste (18.5%)
Attention concentration difficulty (7.4%)
Hyperglycaemia (3.7%)
Sources:
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Disc. AE: Ankle edema, Dizziness...
Other AEs: Sedation, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Ankle edema (4%)
Dizziness (4%)
Other AEs:
Sedation (32%)
Dry mouth (32%)
Postural hypotension (20%)
Weight gain (24%)
Ataxia (8%)
Constipation (12%)
Lethargy (20%)
Edema (8%)
Headache (12%)
Pruritus (12%)
Bad taste (4%)
Nausea (4%)
Diarrhea (4%)
Blurred vision (8%)
Sources:
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
healthy
n = 96
Health Status: healthy
Sex: M+F
Population Size: 96
Sources:
Other AEs: Tachycardia...
Other AEs:
Tachycardia
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
Drowsiness 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
Dry mouth 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
Language disorder 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
Bradycardia grade 3, 20%
Disc. AE
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
Mental concentration difficult
10 % 1 times / day single, topical
Highest studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
Thought disorder
10 % 1 times / day single, topical
Highest studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
Mental status changes
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
healthy, mean age 22.1 years
n = 96
Health Status: healthy
Age Group: mean age 22.1 years
Sex: M+F
Population Size: 96
Sources:
Constipation 18.8%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Dizziness 25%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Malaise 6.3%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Palpitations 6.3%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Sleepiness 68.8%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Dry mouth 75%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
Drowsiness 10%
Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Dry mouth 10%
Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Bad taste 18.5%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Hyperglycaemia 3.7%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Drowsiness 51.8%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Dry mouth 63%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Attention concentration difficulty 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Headache 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Nausea 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Thirst 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Tiredness 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
Constipation 12%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Headache 12%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Pruritus 12%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Lethargy 20%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Postural hypotension 20%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Weight gain 24%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Dry mouth 32%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Sedation 32%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Bad taste 4%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Diarrhea 4%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Nausea 4%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Ankle edema 4%
Disc. AE
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Dizziness 4%
Disc. AE
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Ataxia 8%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Blurred vision 8%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Edema 8%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
Tachycardia
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
healthy
n = 96
Health Status: healthy
Sex: M+F
Population Size: 96
Sources:
Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
[Cardiac arrest following amitriptylin and adrenaline].
1975 Jun 16
Fatal cholestatic jaundice associated with amitriptyline.
2000 Jul-Aug
Near fatal case of atrio-ventricular block induced by amitriptyline at therapeutic dose.
2000 Sep
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.
2001
Gender differences in depression associated with neurologic illness: clinical correlates and pharmacologic response.
2001
Tianeptine: a review of its use in depressive disorders.
2001
Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans.
2001
The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age.
2001
Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis.
2001
Involvement of potassium channels in amitriptyline and clomipramine analgesia.
2001
Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy.
2001 Apr
The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers.
2001 Apr
Noradrenergic dysfunction and antidepressant treatment response.
2001 Apr
Antidepressive treatment with amitriptyline and paroxetine: comparable effects on heart rate variability.
2001 Apr
Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
2001 Apr
[Sensory neuropathy in HIV infection: pathogenesis and therapy].
2001 Apr 14
Controlling phantom limb pain in Sierra Leone.
2001 Apr 21
Postherpetic neuralgia. Treatment with amitriptyline is cheaper than with aciclovir.
2001 Apr 7
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.
2001 Aug
Combined pharmacotherapy for nocturnal enuresis.
2001 Aug
Interaction of psychotropic drugs with monoamine oxidase in rat brain.
2001 Aug
Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine.
2001 Aug
Preventive therapy in pediatric migraine.
2001 Feb
Antidepressant treatment and global tests of coagulation and fibrinolysis.
2001 Feb
Amitriptyline: still efficacious, but at what cost?
2001 Feb
Salmon calcitonin potentiates the analgesia induced by antidepressants.
2001 Jan
Mirtazepine: heir apparent to amitriptyline?
2001 Jan-Feb
Isolated sural neuropathy presenting as lateral ankle pain.
2001 Jul
Cyclobenzaprine and back pain: a meta-analysis.
2001 Jul 9
Efficacy of amitriptyline as a pharmacological adjunct to behavioral modification in the management of aggressive behaviors in dogs.
2001 Jul-Aug
The effect of amitriptyline on pain intensity and perception of stress in bruxers.
2001 Jun
Acute eosinophilic pneumonia associated with amitriptyline in a hemodialysis patient.
2001 Jun
Retro-orbital tumour--an uncommon cause of headache in pregnancy.
2001 Jun
Involvement of adenosine in the effect of antidepressants on glutamate and aspartate release in the rat prefrontal cortex.
2001 Jun
Pharmacological modulation of SK3 channels.
2001 Jun
Corticotropin-releasing hormone perturbations in interstitial cystitis patients: evidence for abnormal sympathetic activity.
2001 Jun
Ring flexibility within tricyclic antidepressant drugs.
2001 Jun
In vitro reaction of formaldehyde with fenfluramine: conversion to N-methyl fenfluramine.
2001 Mar
Cyclobenzaprine hydrochloride is a commonly prescribed centrally acting muscle relaxant, which is structurally similar to tricyclic antidepressants (TCAs) and differs from amitriptyline by only one double bond.
2001 Mar
Discovery of a novel member of the histamine receptor family.
2001 Mar
Effects of amitriptyline on diurnal variations of oxidation-reduction enzyme activities in rat lymphocytes during experimental desynchronosis.
2001 May
Antidepressant drugs in dermatology.
2001 May
Treatment of neuropathic pain with venlafaxine.
2001 May
Advances in the management of neuropathic pain.
2001 May
High-performance liquid chromatographic method combining radiochemical and ultraviolet detection for determination of low activities of uridine 5'-diphosphate-glucuronosyltransferase.
2001 May 15
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
2001 Oct
Efficacy of spinal manipulation for chronic headache: a systematic review.
2001 Sep
Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study.
2001 Sep
HPLC of basic drugs on microparticulate strong cation-exchange materials - a review.
2001 Sep 15
Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care.
2001 Sep 22
Patents

Sample Use Guides

For outpatients, 75 mg of amitriptyline HCl a day in divided doses. If necessary, this may be increased to a total of 150 mg per day. An alternate method of initiating therapy in outpatients is to begin with 50 to 100 mg amitriptyline HCl at bedtime. This may be increased by 25 or 50 mg as necessary in the bedtime dose to a total of 150 mg per day. Hospitalized patients may require 100 mg a day initially. This can be increased gradually to 200 mg a day if necessary up to 300 mg a day. Not recommended for patients under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Amitriptyline was used at 40 uM in isolated rat hepatocytes for 60,120,180 min.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:26:22 UTC 2021
Edited
by admin
on Sat Jun 26 09:26:22 UTC 2021
Record UNII
1806D8D52K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMITRIPTYLINE
INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
AMITRIPTYLINE [USP]
Common Name English
1-PROPANAMINE, 3-(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-
Systematic Name English
LAROXYL
Brand Name English
3-(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-1-PROPANAMINE
Systematic Name English
NORTRIPTYLINE HYDROCHLORIDE IMPURITY F [EP]
Common Name English
AMITRIPTYLINE [MI]
Common Name English
AMITRIPTYLINE [VANDF]
Common Name English
AMITRIPTYLINE [INN]
Common Name English
AMITRIPTYLINE [MART.]
Common Name English
SEROTEN
Common Name English
AMITRIPTYLINE [WHO-DD]
Common Name English
PROHEPTADIENE
Common Name English
TRIPTANOL
Common Name English
DAMITRIPTYLINE
Common Name English
FLAVYL
Common Name English
Classification Tree Code System Code
WHO-ATC N06CA01
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.2.1
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
FDA ORPHAN DRUG 288809
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
WHO-VATC QN06AA09
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
LIVERTOX 44
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
NDF-RT N0000175752
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
FDA ORPHAN DRUG 739620
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
NCI_THESAURUS C94727
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
WHO-VATC QN06CA01
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
WHO-ATC N06AA09
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
Code System Code Type Description
MESH
D000639
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
LACTMED
Amitriptyline
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
WIKIPEDIA
AMITRIPTYLINE
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
HSDB
3007
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
INN
976
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
PUBCHEM
2160
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
IUPHAR
200
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
CAS
50-48-6
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
EVMPD
SUB05462MIG
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
MERCK INDEX
M1753
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C62005
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
RXCUI
704
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL629
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
FDA UNII
1806D8D52K
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
EPA CompTox
50-48-6
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
DRUG BANK
DB00321
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
DRUG CENTRAL
180
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-041-6
Created by admin on Sat Jun 26 09:26:23 UTC 2021 , Edited by admin on Sat Jun 26 09:26:23 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
Metabolizing reaction by CYP2D6: N-demethylation
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INHIBITOR
IC50
BINDING PROTEIN->LIGAND
Amitriptyline displayed an approximately 2:1 [drug:AGP] binding stoichiometry; DETERMINED BY ITC
BINDING
Kd
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
METABOLITE -> PARENT
URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY DEPRESSION, INPATIENTS: 300 MG/DAY

Route of Elimination PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC